Lilley blows Trulicity's core data in a confrontation with Noor and Nord

results data from Trulicity, a diabetes drug, can help it fend off the challenges of Osempic from Noor and Nord.
results of the
REWIND study showed that the weekly GLP-1 agonist Trulicity significantly reduced major adverse cardiovascular events (MACEs) in people with type 2 diabetes, including cardiovascular death, non-fatal myocardial infarction or non-fatal stroke. Placebo is given on top of standard treatment.
results will be presented at future medical conferences - making Trulicity the first type 2 diabetes drug to show the benefits of MACE for undiagnosed cardiovascular patients," Lilley said.
launched its weekly GLP-1 ago ago in the U.S. and said sales rose 804 million Danish kroner ($122 million) in the first nine months of the year, thanks to data showing better blood sugar control than Trulicity when it comes to background therapy for metformin. However, there is still a big gap to catch up with Trulicity, which reached $1.5 billion in the first half of the year.
When the company announces its third-quarter results later, Trulicity will once again be a key driver for Lilly, grabbing market share from Noel and Nord's daily GLP-1 drug Vitoza and whether it can obtain results from its label that it will support the product's competitive image.
Bollinger Ingham and Lilley's SGLT2 inhibitor Jardiance (empagliflozin) are the first FDA-approved drugs that, according to emPA-REG trials, have been competing to generate such data for their products, according to the EMPA-REG trial, which reduces the risk of cardiovascular death in people with type 2 diabetes who have been diagnosed with cardiovascular disease.
, for example, Victoza's LEADER trial also showed a 13% reduced MACE risk, although Johnson and Johnson's CANVAS trial of its SGLT2 inhibitor, Invokana, was less fortunate because the reduction in cardiovascular risk was accompanied by increased amputation of the lower extremities. The immediate question for Lilley is whether Trulicity is fit for Victoza.
and Nord have obtained positive results from Osempic from the SUSTAIN 6 trial, which produced results in 2016, but this is not enough to obtain approved cardiovascular protection instructions because it only statistically shows a non-placebo disadvantage.
the company has discussed a larger results trial for Osempic, but now appears to have adopted a different strategy, testing overweight and obese heart patients for drugs in the SELECT trial to exclude patients with diabetes or elevated blood sugar levels. At the same time, Bollinger Ingeham and Lilley obtained new real-world data from the patient registry showing that the drug reduced the risk of hospitalization for heart failure by 44% compared to DPP4 inhibitors, another widely used type 2 drug for diabetes.
EMPRISE analysis was based on records of approximately 35,000 patients with type 2 diabetes between August 2014 and September 2016, and according to Boehringer, the benefits of Jardiance shown in the EMPA-REG trial were translated into routine clinical care. (This net special draft)